Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    An Enquiry

    Menu

    Kymriah

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Legend, J&J tap Novartis for commercial production of Carvykti
    Legend, J&J tap Novartis for commercial production of Carvykti

    29 Mar 2024

    // FIERCE PHARMA

    https://www.fiercepharma.com/manufacturing/johnson-johnson-legend-expand-manufacturing-deal-novartis-commercial-production

    FIERCE PHARMA
    29 Mar 2024
    Share Share
    NeoImmuneTech to Present Data on NT-I7 in Combo with CAR-T tisagenlecleucel
    NeoImmuneTech to Present Data on NT-I7 in Combo with CAR-T tisagenlecleucel

    04 Nov 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/neoimmunetech-to-present-first-data-on-nt-i7-efineptakin-alfa-in-combination-with-car-t-tisagenlecleucel-at-2022-ash-annual-meeting-301668788.html

    PRNEWSWIRE
    04 Nov 2022
    Share Share
    Novartis five-year Kymriah data show durable remission and long-term survival
    Novartis five-year Kymriah data show durable remission and long-term survival

    12 Jun 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/06/12/2460797/0/en/Novartis-five-year-Kymriah-data-show-durable-remission-and-long-term-survival-maintained-in-children-and-young-adults-with-advanced-B-cell-ALL.html

    GLOBENEWSWIRE
    12 Jun 2022
    Share Share
    FDA approves Novartis Kymriah CAR-T cell therapy for r/r follicular lymphoma
    FDA approves Novartis Kymriah CAR-T cell therapy for r/r follicular lymphoma

    27 May 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/fda-approves-novartis-kymriah-car-t-cell-therapy-for-adult-patients-with-relapsed-or-refractory-follicular-lymphoma-301556984.html

    PRNEWSWIRE
    27 May 2022
    Share Share
    Novartis Kymriah® receives EC approval as first CAR-T cell therapy
    Novartis Kymriah® receives EC approval as first CAR-T cell therapy

    04 May 2022

    // NOVARTIS

    https://www.novartis.com/news/media-releases/novartis-kymriah-receives-ec-approval-first-car-t-cell-therapy-adults-relapsed-or-refractory-follicular-lymphoma

    NOVARTIS
    04 May 2022
    Share Share
    Novartis has an idea why Kymriah failed in 2L lymphoma
    Novartis has an idea why Kymriah failed in 2L lymphoma

    15 Dec 2021

    // Angus Liu FIERCEPHARMA

    https://www.fiercepharma.com/pharma/novartis-has-idea-why-kymriah-failed-lymphoma-shifts-focus-to-next-gen-car-t

    Angus Liu FIERCEPHARMA
    15 Dec 2021
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.